Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 4/20 | 0.40 |
| ▸ | TOP1 | P11387 | 4/20 | 0.39 |
| ▸ | CYCS | P99999 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075062 | 0.91 | ABCG2 (0.47) | ABCG2TERTTOP1CYCSCNR1 | |
| SCHEMBL10050496 | 0.91 | MAPT (0.36) | ABCG2TERTTOP1CYCSCNR1 | |
| SCHEMBL10050497 | 0.84 | RAB9A (0.44) | MEN1KMT2A | |
| SCHEMBL10050507 | 0.81 | TERT (0.41) | ABCG2TERTTOP1CYCSCNR1 | |
| SCHEMBL29414382 | 0.80 | TERT (0.57) | ABCG2TERTTOP1CYCSENPP2 | |
| SCHEMBL29777544 | 0.80 | TOP1 (0.55) | ABCG2TERTTOP1CYCSENPP2 | |
| SCHEMBL6513665 | 0.80 | TOP1 (0.55) | ABCG2TERTTOP1CYCSENPP2 | |
| SCHEMBL949511 | 0.80 | TERT (0.57) | ABCG2TERTTOP1CYCSENPP2 | |
| SCHEMBL10050500 | 0.79 | MAPT (0.39) | ABCG2CNR1GSK3B | |
| SCHEMBL2338257 | 0.79 | TERT (0.55) | ABCG2TERTTOP1CYCSENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | EPS15, PPOX, ACR | ABCG2 703/4885TERT 1074/4885TOP1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.